- Global Pharma News & Resources

Oxycodone Market will increase at a steady 4.8% CAGR by 2031 | FMI Analyst

According to a newly updated analysis from Future Market Insights, Oxycodone Market will increase steadily between 2021 and 2031 at a CAGR of 4.8%. The market for oxycodone is expected to reach a value of over US$ 4.6 Billion in 2021, driven by a surge in demand for efficient pain treatment options.

Despite growing healthcare expenses in the United States and Canada, growth projections for North America are hopeful. As a result, the price of oxycodone in North America is expected to reach US$ 1.85 billion in 2021.

Oxycodone is an opioid analgesic that is commonly used in pain treatment. It is utilised for both long and short periods of time. The rising frequency of orthopaedic illnesses such as osteoporosis, fibromyalgia, rheumatoid arthritis, and other kinds of chronic pain is driving the global demand for oxycodone.

For More Insights on this Market, Get A Sample Report @

According to the International Osteoporosis Foundation, osteoporosis is one of the most serious health concerns among women and around 30% of people in U.S and Europe are affected by it each year. Increasing medical ailment and post-operative pain is another factor influencing the demand for oxycodone market globally.

The market growth is expected to accelerate due to increasing research and development activities undertaken to innovate abuse-deterrent formulations. Advance drug formulation such as extended-release medication for pain relief is an example of improve formulation.

The market however could face certain restrains in growth as oxycodone has side effects such as bladder pain, abdominal cramps, vomiting, diarrhoea, and breathing problem. Moreover, overdose of oxycodone can lead to de-addiction. The market can also be impacted due to certain severe adverse psychological problems such as depression.

Have a Conversation with the Analyst @

Key Takeaways from FMI’s Oxycodone Market Study

  • Increasing penetration of pain management drugs, coupled with favourable reimbursement policies will drive sales in the U.S.
  • Within the Middle East and Africa, the demand in GCC countries will rise backed by investment towards expansion of the healthcare sector
  • The U.K., Italy, and France are likely to account for sizeable share in the Europe market for oxycodone
  • Long-acting oxycodone sales will rise steadily owing to surging application in pain management
  • Hospital pharmacies will continue exhibiting high demand for oxycodone, driven by higher footfall of patients

Who is Winning?

  • FDA in 2017 approved RoxyBond, a novel formulation of immediate-release oxycodone. This is the first approved immediate release opioid analgesic formulation with labelling that describes its abuse-deterrent properties.
  • In September 2019, Daiichi Sankyo Company in Japan, launched its generic formulated oxycodone hydrochloride hydrate extended release tablets for cancer pain treatment.

Didn’t find the data you are looking for? Our experts provide you customized reports @

Key Companies Profiled:

  • Teva Pharmaceutical Industries Ltd.
  • Purdue Pharma L.P
  • Daiichi Sankyo
  • Acorda Therapeutics
  • Teikoku Pharma USA, Inc.
  • Mylan N.V
  • Endo Pharmaceuticals Inc.
  • Janssen Pharmaceuticals, Inc.

Key Segments Covered in Oxycodone Market Study

By Oxycodone Type:

  • Long-acting oxycodone
  • Short-acting oxycodone

By Application:

  • Pain Management
  • De-addiction

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.


Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries:
Browse All Reports:

Editor Details

Last Updated: 22-Apr-2023